AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference in September.
| Event: | H.C. Wainwright 24th Annual Global Investment Conference – September 12th-14th | |
| Presentation: | Pre-recorded presentation available beginning September 12th at 7:00 AM (EDT) | |
| Webcast link: | Here | |
| 1×1 Meetings: | Management will be available for one-on-one meetings during the conference, September 12th-14th |
The webcast for the presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your H.C. Wainwright salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
The world's first modular exoskeleton combines quasi-direct-drive hip and cable-drive knee technologies for natural, powerful…
Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral 'New…
The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing…
MESA, Ariz., Jan. 9, 2026 /PRNewswire/ -- Gifthealth, a unified digital pharmacy platform, today celebrated the…
NASHVILLE, Tenn., Jan. 9, 2026 /PRNewswire/ -- Today, Lucent Health, one of the nation's largest independent…